Amplimmune Immunology
Founded Year
2000Stage
Acquired | AcquiredTotal Raised
$20MValuation
$0000About Amplimmune Immunology
Amplimmune is a product driven company that is developing immune-based biologics to treat patients in the areas of cancer, autoimmunity, transplantation and infectious diseases. Amplimmune's scientific founders from Johns Hopkins University have identified several key immunological ligands and receptors. These immunological checkpoint and co-stimulatory molecules are the basis for developing a new class of biological treatments which modulate critical mechanisms in the body's immune system with the aim of bettering the lives of patients suffering from aberrant immunological conditions.
Loading...
Loading...
Amplimmune Immunology Patents
Amplimmune Immunology has filed 12 patents.
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
5/27/2014 | 6/11/2019 | Clusters of differentiation, Immunology, Immune system, Transcription factors, Monoclonal antibodies | Grant |
Application Date | 5/27/2014 |
|---|---|
Grant Date | 6/11/2019 |
Title | |
Related Topics | Clusters of differentiation, Immunology, Immune system, Transcription factors, Monoclonal antibodies |
Status | Grant |
Amplimmune Immunology Frequently Asked Questions (FAQ)
When was Amplimmune Immunology founded?
Amplimmune Immunology was founded in 2000.
Where is Amplimmune Immunology's headquarters?
Amplimmune Immunology's headquarters is located at 45 West Watkins Mill Road, Gaithersburg.
What is Amplimmune Immunology's latest funding round?
Amplimmune Immunology's latest funding round is Acquired.
How much did Amplimmune Immunology raise?
Amplimmune Immunology raised a total of $20M.
Who are the investors of Amplimmune Immunology?
Investors of Amplimmune Immunology include MedImmune, InterWest Partners and Wellcome Trust.
Who are Amplimmune Immunology's competitors?
Competitors of Amplimmune Immunology include ISA Pharmaceuticals, Activate Immunotherapy, Syndax Pharmaceuticals, Theraclone Sciences, FibroGen and 7 more.
Loading...
Compare Amplimmune Immunology to Competitors
CoImmune, fka Argos Therapeutics, is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases. Using biological components from each patient, the company's immunotherapies employ the patient's dendritic cells to activate an immune response specific to the patient's disease.
Theraclone Sciences is a biotechnology company focused on the development of therapeutic products. The company's main offering is a comprehensive screening technology that identifies effective human monoclonal antibodies, which are used in the treatment of various diseases. Theraclone Sciences primarily serves the healthcare and pharmaceutical industries. It is based in Seattle, Washington.
BioMs develops biologics for autoimmune diseases with a special emphasis on multiple sclerosis.
Onyvax is developing new cancer therapies that harness the selective power of the immune system to seek out and destroy tumor cells. Onyvax's products specifically target cancer cells, increasing the likelihood that they will be effective while minimising side effects associated with many conventional treatments. These therapies can broadly be classed as therapeutic cancer vaccines. Onyvax's lead product is in clinical trials for the treatment of prostate cancer and is poised to enter the final stages of development. Onyvax is committed to the commercialisation of therapies that enhance survival while maintaining a high quality of life for patients. The Company is based in London and has collaborations with leading hospitals and other institutions throughout Europe and the US.
Neotropix 1 is a virotherapy company, dedicated to the development and commercialization of virus-based therapies for the treatment of cancer and other diseases. Per Neotropix, virotherapy holds great promise for cancer patients because it may be more efficacious and less toxic than conventional radiation and chemotherapy.
PNP Therapeutics is dedicated to the development and commercialization of a cancer treatment approach that is predicated on well-documented evidence that solid tumors can be compelled to develop their own chemotherapy and thus elicit their own self-destruction.
Loading...